# US 2008/0287422 A1 · Constrained Compounds as CGRP-Receptor Antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287422 A1
- Document ID: US20080287422A1
- Status: Published application
- Kind: A1
- Application number: 12/105,434
- Filed: 2008-04-18
- Published: 2008-11-20
- Earliest claimed: 2005-10-11
- Assignees: Bristol-Myers Squibb Company
- Inventors: Prasad V. Chaturvedula; Stephen E. Mercer; Haiquan Fang
- Web page: https://patentgrep.com/patent/US20080287422A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 15/12: for climacteric disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

## Claims

### Claim 1

A compound of Formula I
wherein:
R1 is C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, C5-7cycloalkenyl, C1-6(C3-7cycloalkyl)alkyl, C1-6haloalkyl, C1-6(C1-6alkoxy)alkyl, C1-6(Ar1)alkyl, C1-6(NR7R8)alkyl, N—(R9)-pyrrolidinyl or N—(R9)-piperidinyl;
R2 is hydrogen, halo, hydroxy, C1-6alkyl, C2-6alkenyl, benzyloxy, or NR7R8;
R3 is hydrogen, hydroxy, halo, C1-6alkyl, or C2-6alkenyl;
or R2 and R3 taken together are CHNNR5;
R4 is hydrogen, halo or C1-6alkyl, or C2-6alkenyl;
R5 is hydrogen or C1-6alkyl;
R6 is hydrogen, C1-6alkyl,
or NR5R6 taken together is
R7 is hydrogen or C1-6alkyl;
R8 is hydrogen or C1-6alkyl; or
NR7R8 taken together is selected from the group consisting of pyrrolidinyl, piperidinyl, N—(R9)-piperazinyl, morpholinyl, and thiomorpholinyl;
R9 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, or C1-6alkoxycarbonyl;
R10 is phenyl, naphthyl, pyridinyl, pyridinyl N-oxide, quinolinyl, quinolinyl N-oxide, isoquinolinyl, or isoquinolinyl N-oxide, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy, and phenyl;
or R10 is selected from the group consisting of
each R11 is independently hydrogen, halo, C1-6alkyl, C1-6haloalkyl, or C1-6alkoxy;
Ar1 is phenyl, naphthyl, pyridinyl, or imidazolyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
Ar2 is phenyl, naphthyl, or pyridinyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
X—Y is aminocarbonyl, oxycarbonyl, methylenecarbonyl, ethylene, or amino(cyano)iminomethyl;
Z is N or CH; and
n is 0 or 1;
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2

A compound of Formula II
where
R1 is C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, C5-7cycloalkenyl, C1-6(C3-7cycloalkyl)alkyl, C1-6haloalkyl, C1-6(C1-6alkoxy)alkyl, C1-6(Ar1)alkyl, C1-6(NR7R8)alkyl, N—(R9)-pyrrolidinyl or N—(R9)-piperidinyl;
R4 is hydrogen, halo or C1-6alkyl, or C2-6alkenyl;
R5 is hydrogen or C1-6alkyl;
R6 is hydrogen, C1-6alkyl,
or NR5R6 taken together is
R7 is hydrogen or C1-6alkyl;
R8 is hydrogen or C1-6alkyl; or
NR7R8 taken together is selected from the group consisting of pyrrolidinyl, piperidinyl, N—(R9)-piperazinyl, morpholinyl, and thiomorpholinyl;
R9 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, or C1-6alkoxycarbonyl;
R10 is phenyl, naphthyl, pyridinyl, pyridinyl N-oxide, quinolinyl, quinolinyl N-oxide, isoquinolinyl, or isoquinolinyl N-oxide, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy, and phenyl;
or R10 is selected from the group consisting of
each R11 is independently hydrogen, halo, C1-6alkyl, C1-6haloalkyl, or C1-6alkoxy;
Ar1 is phenyl, naphthyl, pyridinyl, or imidazolyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
Ar2 is phenyl, naphthyl, or pyridinyl, and is substituted with 0-2 substituents selected from the group consisting of halo, C1-6alkyl, and C1-6haloalkyl;
X—Y is aminocarbonyl, oxycarbonyl, methylenecarbonyl, ethylene, or amino(cyano)iminomethyl;
Z is N or CH; and
the carbon bearing the asterisk is either the (S) configuration or the (R) configuration;
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 3 (depends on 2)

A compound of claim 2 where the carbon bearing the asterisk is of the (S) configuration.

### Claim 4 (depends on 1, 2)

A compound of claim 1 or 2 where R4 is chloro, fluoro, or methyl.

### Claim 5 (depends on 1, 2)

A compound of claim 1 or 2 where NR5R6 taken together is

### Claim 6 (depends on 1, 2)

A compound of claim 1 or 2 where NR5R6 taken together is

### Claim 7 (depends on 1, 2)

A compound of claim 1 or 2 where R10 is selected from the group consisting of

### Claim 8 (depends on 1, 2)

A compound of claim 1 or 2 where R11 is hydrogen, chloro, fluoro, or methyl.

### Claim 9 (depends on 1, 2)

A compound of claim 1 or 2 where Z is CH.

### Claim 10 (depends on 1)

A compound of claim 1 where n is 1.

### Claim 11 (depends on 1)

A composition comprising a compound of claim 1 and a pharmaceutically acceptable adjuvant, carrier, or diluent.

### Claim 12 (depends on 1)

A method of treating migraine comprising the administration of a therapeutically effective amount of a compound of claim 1 to a patient.

### Claim 13 (depends on 2)

A composition comprising a compound of claim 2 and a pharmaceutically acceptable adjuvant, carrier, or diluent.

### Claim 14 (depends on 2)

A method of treating migraine comprising the administration of a therapeutically effective amount of a compound of claim 2 to a patient.
